

Aspira Women's Health Appoints Three New Members to its Board of Directors

Description

May 09, 2023 16:07 ET

AUSTIN, Texas, May 09, 2023 (GLOBE NEWSWIRE) — Aspira Women's Health Inc. ("Aspira") (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of three new independent directors: Stefanie Cavanaugh, Jannie Herchuck, and Lynn O'Connor Vos.

"We are thrilled to welcome Stefanie, Jannie and Lynn to our Board of Directors," said **Dr. Veronica Jordan, Chairwoman of the Aspira Board of Directors**. "Aspira has been through tremendous change this past year, and attracting top talent is a testament to the strength of the technology, strategy and potential as a company. We look forward to their guidance as we continue to grow and unlock the tremendous potential to improve the treatment pathway for all women."

Nicole Sandford, President and Chief Executive Officer of Aspira Women's Health said, "We warmly welcome our new members to the Aspira Board of Directors. Stefanie, Jannie and Lynn are very experienced and extraordinarily successful executives who bring a passion for improving women's lives. I look forward to working closely with them as we move swiftly to the next level of growth."

Ms Stefanie Cavanaugh joins the Board as a seasoned executive having been a senior financial executive for healthcare companies for over 30 years. Ms. Cavanaugh currently serves as Chief Financial Officer of Giving Home Health Care, an at-home healthcare services company.

Ms. Jannie Herchuck served in various roles at Deloitte & Touche since 1985 until her retirement as an audit partner in 2022. Ms. Herchuck most recently served on the Deloitte LLP board of directors leading strategic initiatives and practices.

Ms. Lynn O'Connor Vos is a healthcare CEO and Board Director with experience across product launches, global marketing, digital health, and M&A. She founded her own healthcare consultancy firm after having served as interim CEO of Modular Medical, Inc. She spent nearly 30 years as CEO of Greyhealth Group where she built a global healthcare communications firm and worked on launches for clients across the pharmaceutical, biotech, surgical and diagnostic sectors.

About Aspira Women's Health Inc.

Aspira Women's Health Inc. is transforming women's gynecological health with the discovery, development, and commercialization of innovative testing options for women of all races and ethnicities, starting with ovarian cancer.

Our ovarian cancer risk assessment portfolio is marketed to healthcare providers as OvaSuite. OvaWatch SM

is a non-invasive, blood-based test intended for use in the initial clinical assessment of ovarian cancer risk in women with benign or indeterminate adnexal masses for which surgical intervention may be either premature or unnecessary. With a negative predictive value (NPV) of 99%, OvaWatch allows physicians to confidently rule out ovarian cancer malignancy and choose the appropriate clinical management for the right patient at the right time. Ova1Plus[®] combines our FDA-cleared products, Ova1[®] and Overa[®], to detect risk of ovarian malignancy in women with adnexal masses planned for surgery.

EndoCheck[™], Aspira's first-of-its-kind non-invasive diagnostic test for endometriosis, is currently in development. Visit our website for more information at www.aspirawh.com.

Forward-Looking Statements

This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the planned launches of our serial monitoring test and our EndoCheck diagnostic blood test by the end of 2023. Forward-looking statements involve a number of risks and uncertainties. Words such as “may,” “expects,” “intends,” “anticipates,” “believes,” “estimates,” “plans,” “seeks,” “could,” “should,” “continue,” “will,” “potential,” “projects” and similar expressions are intended to identify forward-looking statements. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including those described in the section entitled “Risk Factors” in Aspira’s Annual Report on Form 10-K for the year ended December 31, 2022. These risks include, but are not limited to: our ability to continue as a going concern; our ability to comply with Nasdaq’s continued listing requirements; impacts resulting from potential changes to coverage of Ova1 through our Medicare Administrative Carrier for Ova1; impacts resulting from or relating to the COVID-19 pandemic and actions taken to contain it; anticipated use of capital and its effects; our ability to increase the volume of our product sales; failures by third-party payers to reimburse for our products and services or changes to reimbursement rates; our ability to continue developing existing technologies and to develop, protect and promote our proprietary technologies; plans to develop and perform laboratory developed tests; our ability to comply with Food and Drug Administration (“FDA”) regulations that relate to our products and to obtain any FDA clearance or approval required to develop and commercialize medical devices; our ability to develop and commercialize additional diagnostic products and achieve market acceptance with respect to these products; our ability to compete successfully; our ability to obtain any regulatory approval required for our future diagnostic products; or our suppliers’ ability to comply with FDA requirements for production, marketing and post-market monitoring of our products; our ability to maintain sufficient or acceptable supplies of immunoassay kits from our suppliers; in the event that we succeed in commercializing our products outside the United States, the political, economic and other conditions affecting other countries; changes in healthcare policy; our ability to comply with environmental laws; our ability to comply with the additional laws and regulations that apply to us in connection with the operation of ASPIRA LABS; our ability to use our net operating loss carryforwards; our ability to use intellectual property; our ability to successfully defend our proprietary technology against third parties; our ability to obtain licenses in the event a third party successfully asserts proprietary rights; the liquidity and trading volume of our common stock; material weaknesses in our internal control over financial reporting; the concentration of ownership of our common stock; our ability to retain key employees; our ability to secure additional capital on acceptable terms to execute our business plan; business interruptions; the effectiveness and availability of our information systems; our ability to

integrate and achieve anticipated results from any acquisitions or strategic alliances; future litigation against us, including infringement of intellectual property and product liability exposure; and additional costs that may be required to make further improvements to our laboratory operations. The events and circumstances reflected in Aspira's forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Aspira expressly disclaims any obligation to update, amend or clarify any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

Investor Relations Contact:

Monique Kosse
Managing Director
LifeSci Advisors, LLC
Tel: 212-915-3820